1136PPhase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis

ConclusionsP vs E showed favorable OS in Asia and non-Asia subgrps, regardless of PD-L1 status; responses were durable, particularly among all non-Asia subgrps; safety was favorable. P+C vs E showed favorable OS in pts with CPS ≥20 in Asia and non-Asia subgrps regardless of PD-L1 status, durable responses, and similar safety.Clinical trial identificationNCT02358031.Editorial acknowledgementDoyel Mitra, PhD, and Dana Francis, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA), funded by Merck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.Legal entity responsible for the studyMerck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA Table: 1136PAsia, CPS ≥20Asia, CPS ≥1Asia, Total PopulationNon-Asia, CPS ≥20Non-Asia, CPS ≥1Non-Asia, Total PopulationP vs E n = 22 vs 23P+C vs E n = 22 vs 21P vs E n = 48 vs 46P+C vs E n = 45 vs 43P vs E n = 56 vs 53P+C vs E n = 57 vs 49P vs E n = 111 vs 99P+C vs E n = 104 vs 89P vs E n = 209 vs 209P+C vs E n = 197 vs 192P vs E n = 245 vs 247P+C vs E n = 224 vs 229OS: HR (95% CI )0.39 (0.19-0.80)0.80 (0.41-1.58)0.80 (0.51-1.27)1.13 (0.71-1.79)0.74 (0.48-1.13)1.03 (0.68-1.58)0.75 (0.54-1.04)0.68 (0.48-0.96)0.76 (0.61-0.95)0.65 (0.51-0.82)0.87 (0.71-1.06)0.71 ( 0.57-0.88)PFS: HR (95% CI)1.16 (0.63-2.11)1.07 (0.58-1.99)1.25 (0.82-1.91)1.14 (0.74-1.76)1.39 (0.94-2.05)1.12 (0.75-1.66)0.95 (0.70-1.28)0.65 (0.47-0.89)1.10 (0...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research